andrewkaretas, Author at Allogene

8-K: Report of unscheduled material events or corporate event

Post author:andrewkaretas
Post published:October 14, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

October 2, 2025 1:00 PM EDT : Citi’s SMID call series

Post author:andrewkaretas
Post published:September 19, 2025
Post category:Events

September 3, 2025 10:30 AM EDT : Citi’s 2025 Biopharma Back to School Conference

Post author:andrewkaretas
Post published:August 29, 2025
Post category:Events

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Post author:andrewkaretas
Post published:August 27, 2025
Post category:Latest News

SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…

10-Q: Quarterly report which provides a continuing view of a company’s financial position

Post author:andrewkaretas
Post published:August 13, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

8-K: Report of unscheduled material events or corporate event

Post author:andrewkaretas
Post published:August 13, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Post author:andrewkaretas
Post published:August 13, 2025
Post category:Latest News

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard…